Mycophen Dosage/Direction for Use

Renal Transplant: Adults: Mycophenolate should be initiated within 72 hrs following transplantation. The recommended dose is 1 g administered twice daily (2 g daily dose).
Children and Adolescents 2-18 years: 600 mg/m² administered orally twice daily (up to a maximum of 2 g daily). Children <2 years: Not recommended.
Cardiac Transplant: Adults: Mycophenolate should be initiated within 5 days following transplantation. The recommended dose is 1.5 g administered twice daily (3 g daily dose). Children: No data are available for pediatric cardiac transplant patients.
Hepatic Transplant: Adults: Mycophenolate IV should be administered for the first 4 days following hepatic transplant with oral mycophenolate initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose). Children: No data are available for pediatric transplant patients.
Use in elderly (65 years): 1 g administered twice daily for renal transplant patients and 1.5 g twice daily for cardiac or hepatic transplant patients is appropriate for the elderly.
Renal Impairment: In renal transplant patients with severe chronic renal impairment (glomerular filtration rate <25 mL·min^-1·1.73 m^-2), outside the immediate post-transplant period, doses >1 g administered twice daily should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delay renal graft function post-operatively. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.
Severe Hepatic Impairment: No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.
Treatment During Rejection Episodes: Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of mycophenolate is not required. There is no basis for mycophenolate dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection.